Related Experiment Videos
An expression signature classifies chemotherapy-resistant pediatric osteosarcoma
Michelle B Mintz1, Rebecca Sowers, Kevin M Brown
1Neurogenomics Division and Genetic Basis of Human Disease Division, Translational Genomics Research Institute, Phoenix, Arizona 85004, USA.
Cancer Research
|March 9, 2005
Summary
This study identified genes linked to poor osteosarcoma chemotherapy response. Targeting extracellular matrix remodeling and osteoclast differentiation may improve treatment outcomes for pediatric bone cancer patients.
Area of Science:
- Oncology
- Genomics
- Biomarkers
Background:
- Osteosarcoma is the most common pediatric bone cancer.
- Poor chemotherapy response in osteosarcoma patients correlates with higher relapse risk and adverse outcomes.
Purpose of the Study:
- Identify prognostic factors at diagnosis for osteosarcoma.
- Characterize genes predicting poor survival.
- Discover novel therapeutic targets for osteosarcoma.
Main Methods:
- Gene expression profiling of 30 osteosarcoma biopsy samples using microarrays.
- Differential expression analysis between chemotherapy responders (Huvos III/IV) and non-responders (Huvos I/II).
- Validation of significant genes using quantitative reverse transcription-PCR on xenograft samples.
Main Results:
- Identified 104 statistically significant differentially expressed genes between response groups.
- Genes associated with poor response (Huvos I/II) include those in extracellular matrix (ECM) remodeling and osteoclast differentiation.
- Significant decrease in osteoprotegerin (OPG) observed in non-responders; other key genes include annexin 2, SMAD, PLA2G2A, TGFbeta1, desmoplakin, SPARCL1, biglycan, and PECAM.
Conclusions:
- Osteosarcoma tumor-driven alterations in the bone microenvironment may contribute to chemotherapy resistance.
- Potential therapeutic strategies could target ECM remodeling and osteoclastogenesis pathways to enhance treatment response.